Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Memory: therapeutic approach. Clinical evaluation].

F Pasquier1

  • 1Centre de la Mémoire, Clinique Neurologique, CHRU 59037 Lille, France.

Therapie
|December 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Leukemia & lymphoma·2020
Same author

Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.

Drugs of today (Barcelona, Spain : 1998)·2020
Same author

17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression.

Molecular psychiatry·2016
Same author

[Alzheimer's disease cerebro-spinal fluid biomarkers: A clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases].

La Revue de medecine interne·2016
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
Same journal

[Efficacy of celecoxib, diclofenac, etoricoxib, ibuprofen, ketoprofen and naproxen in low back pain with or without nerve root pain: Systematic review of literature and meta-analysis of randomized controlled trials].

Therapie·2026
Same journal

Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN).

Therapie·2026
See all related articles

Pharmaceutical trials primarily assess episodic memory in Alzheimer's disease, following agency guidelines. However, other memory types like autobiographical and prospective memory remain underexplored in drug development.

Area of Science:

  • Neuroscience
  • Psychology
  • Clinical Trials

Context:

  • Memory assessment is crucial in pharmaceutical trials, particularly for Alzheimer's disease.
  • Regulatory agencies provide guidelines for memory test selection, emphasizing simplicity, brevity, and sensitivity.
  • Existing memory tests must possess inter-rater reliability, face validity, cross-cultural adaptability, and parallel forms to prevent training effects.

Purpose:

  • To review current practices in memory assessment for pharmaceutical trials.
  • To highlight the limitations of existing memory tests in capturing the full spectrum of memory functions.
  • To identify underexplored memory domains in drug development research.

Summary:

  • Current pharmaceutical trials predominantly focus on episodic memory assessment, often using the ADAS-Cog scale, which has been instrumental in approving Alzheimer's disease treatments.

Related Experiment Videos

  • While guidelines exist for test selection, they primarily address episodic memory and do not encompass other critical memory systems.
  • Autobiographical, remote, prospective memory, and metamemory have not been adequately explored in pharmaceutical trial settings.

    • Impact:

    • This review underscores the need for broader memory assessment in pharmaceutical trials beyond episodic memory.
    • Expanding assessment to include autobiographical, remote, prospective memory, and metamemory could lead to more comprehensive drug efficacy evaluations.
    • Future research should focus on developing and validating instruments to assess these under-explored memory domains for improved clinical trial design.